Physician profile
Nicole M Bails
NPI 1467149831
$4,478.23
in general payments reported to CMS, 2019-2025
16 companies · $2,983 in 2025
The $2,983 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $543 · 2024: $952 · 2025: $2,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,931 · Travel and Lodging: $1,418 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,930.57 |
| Travel and Lodging | $1,417.66 |
| Education | $130.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,497.03 | 2023-2025 | Watchman, Watchman Flx |
| Edwards Lifesciences Corporation | $1,295.38 | 2024-2025 | Sapien 3 Ultra Resilia |
| Cvrx, INC. | $350.48 | 2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $323.54 | 2023-2024 | Xarelto |
| Medtronic, INC. | $188.03 | 2024 | Corevalve Evolut R, Azure Xt Dr Mri Surescan, Mycarelink |
| Amgen INC. | $172.65 | 2023-2024 | Repatha |
| Pacira Pharmaceuticals Incorporated | $129.27 | 2023 | Exparel |
| United Therapeutics Corporation | $115.15 | 2024 | |
| Novartis Pharmaceuticals Corporation | $104.66 | 2023-2025 | |
| Novo Nordisk INC | $93.59 | 2023-2025 | Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $56.27 | 2024 | Eliquis |
| Atricure, INC. | $47.94 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $31.23 | 2023-2025 | Farxiga |
| Cleerly, INC. | $29.32 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Sanofi-Aventis U.S. LLC | $27.64 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.05 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Bails listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.